2 completed, 2 terminated. 2 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Maroteaux-Lamy Syndrome: new trials by email Literature Review of Maroteaux-Lamy Syndrome trials Research Report on Maroteaux-Lamy Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome Naglazyme® - Maroteaux-Lamy Syndrome | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 1 | 2016-01-26 | 2020-12-23 |
| Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Campath-1H, Cyclophosphamide, Busulfan - Mucopolysaccharidosis, Hurler Syndrome | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 46 | 2009-12-01 | 2018-02-05 |
| Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Stem Cell Transplantation, Cyclophosphamide, Campath-1H - Hurler's Syndrome, Maroteaux-Lamy Syndrome | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 18 | 2008-03-01 | 2017-12-28 |
| A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI Naglazyme - Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome | Phase 4 | Completed | BioMarin Pharmaceutical | 4 | 2006-05-01 | 2011-07-22 |
Mucopolysaccharidosis VI (4) · Aspartylglucosaminuria (2) · Fucosidosis (2) · Leukodystrophy, Globoid Cell (2) · Leukodystrophy, Metachromatic (2) · Mucopolysaccharidosis I (2) · Mucopolysaccharidosis VII (2) · Peroxisomal Disorders (2) · Sphingolipidoses (2) · alpha-Mannosidosis (2) · Adrenoleukodystrophy (1) · Metabolism, Inborn Errors (1) · Mucopolysaccharidoses (1) · Mucopolysaccharidosis II (1) · Niemann-Pick Disease, Type B (1)
Carbohydrate Metabolism, Inborn Errors (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Connective Tissue Diseases (4) · Genetic Diseases, Inborn (4) · Lysosomal Storage Diseases (4) · Metabolic Diseases (4) · Mucinoses (4) · Nutritional and Metabolic Diseases (4) · Skin and Connective Tissue Diseases (4) · Metabolism, Inborn Errors (3) · Mucopolysaccharidoses (3) · Brain Diseases (2) · Brain Diseases, Metabolic (2) · Brain Diseases, Metabolic, Inborn (2) · Central Nervous System Diseases (2)
Alemtuzumab (2) · Busulfan (2) · Cyclophosphamide (2) · Stem Cell Transplantation (2) · galsulfase (2) · Bone Marrow Transplantation (1) · Cyclosporine (1) · Mycophenolic Acid (1)
Masonic Cancer Center, University of Minnesota (3) · BioMarin Pharmaceutical (1)
United States (4) · France (1) · Portugal (1)
Paul Orchard, MD (2) · Celeste Decker, MD (1) · Elizabeth Braulin, M.D. (1)